Abstract:Background: Serological screening of the relatives of coeliac disease patients is widely endorsed. However, the need for and the optimal timing of possible re-testing of once seronegative at-risk individuals for coeliac disease remain unclear. Objective: We investigated this issue by inviting a large cohort of previously screening-negative relatives of patients with coeliac disease to participate in a follow-up study. Methods: Altogether 599 relatives of coeliac disease index patients not diagnosed with coeliac disease in a screening study carried out in 2006-2010 were asked about possible later diagnosis or re-tested with coeliac disease autoantibodies in 2017-2021. Besides incidence, the possible impact of various patient-related clinical factors and HLA haplotype on the later diagnosis or screening positivity was examined. Results: Fifteen (2.5%) relatives were either diagnosed with a coeliac disease (n = 8) during the follow-up period or were found to be screening-positive in the re-testing (n = 7), giving a combined annual incidence of 221/100,000 person-years in all relatives and 336/100,000 among those carrying coeliac disease-associated HLA DQ2/DQ8. The new cases more often carried the high-risk (DQ2.5/2.5 or DQ2.5/2.2; 35.7% vs. 7.4%, respectively, p < 0.001) HLA and were younger at initial screening (23.3 vs. 40.5 years, p = 0.028) and - in spite of a negative screening outcome - had higher median transglutaminase antibody level in the first study than those not affected. There were no significant differences between the affected and non-affected relatives in other demographic data, degree of kinship with the index, current symptoms or frequency of chronic co-morbidities. Conclusion: The incidence rate for later coeliac disease diagnosis or new seropositivity in relatives who had been tested once was 221/100,000 person-years in all and 336/100,000 among those carrying at-risk HLA genetics after ∼10 years of follow-up. HLA-typing could help to target a subgroup of relatives who would benefit most from re-testing.

Longitudinal screening of HLA‐risk and HLA‐nonrisk children for celiac disease to age 15 years: CiPiS study

Accuracy of Serological Screening for the Diagnosis of Celiac Disease in Type 1 Diabetes Children

Celiac disease can be predicted by high levels of tissue transglutaminase antibodies in children and adolescents with type 1 diabetes

Genomewide Linkage Analysis of Celiac Disease in Finnish Families.

Coeliac disease re-screening among once seronegative at-risk relatives: A long-term follow-up study

Prevalence and detection rate of celiac disease in Italy: Results of a SIGENP multicenter screening in school-age children

Prevalence and Predictive Factors for Celiac Disease in Children With Type 1 Diabetes. Whom and When to Screen? A Nationwide Longitudinal Cohort Study of Swedish Children

Diagnosing Coeliac Disease During Mass-Screening of General Paediatric Population: Is Biopsy Avoidable?

Long-term health and treatment outcomes in adult coeliac disease patients diagnosed by screening in childhood

Potential Celiac Disease in Children: Health Status on a Long-Term Gluten-Containing Diet

Home capillary sampling and screening for type 1 diabetes, celiac disease, and autoimmune thyroid disease in a Swedish general pediatric population: the TRIAD study

Antibodies to Gliadin by ELISA as a Screening Test for Childhood Celiac Disease

Associations of dietary patterns between age 9 and 24 months with risk of celiac disease autoimmunity and celiac disease among children at increased risk

HLA genotyping in children with celiac disease allows to establish the risk of developing type 1 diabetes.

Gut microbiome markers in subgroups of HLA class II genotyped infants signal future celiac disease in the general population: ABIS study

Screening for celiac disease among children with overweight and obesity: toward exploring celiac iceberg

Clinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years

Incidence of Pediatric Celiac Disease Varies by Region

Adherence to dietary treatment and clinical factors associated with anti-transglutaminase antibodies in celiac disease during the follow-up

Outcome in pediatric celiac disease is independent of the diagnostic approach in patients with high antibody levels

The Diagnostic Value of the Gliadin Antibody Test in Celiac Disease in Children